# Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

> **NCT04384692** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 53 (actual)

## Conditions studied

- Primary Myelofibrosis
- Secondary Myelofibrosis

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Methotrexate
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Ruxolitinib
- **DRUG:** Tacrolimus
- **RADIATION:** Total-Body Irradiation
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Ultrasound Imaging

## Key facts

- **NCT ID:** NCT04384692
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-18
- **Primary completion:** 2026-04-03
- **Final completion:** 2030-04-23
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04384692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04384692, "Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04384692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*